CA1281288C - Tumor therapy - Google Patents

Tumor therapy

Info

Publication number
CA1281288C
CA1281288C CA000493821A CA493821A CA1281288C CA 1281288 C CA1281288 C CA 1281288C CA 000493821 A CA000493821 A CA 000493821A CA 493821 A CA493821 A CA 493821A CA 1281288 C CA1281288 C CA 1281288C
Authority
CA
Canada
Prior art keywords
proline
amino acids
hydroxy
cis
hydroxyproline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000493821A
Other languages
English (en)
French (fr)
Inventor
Wilhelm Hoerrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA1281288C publication Critical patent/CA1281288C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
CA000493821A 1984-11-05 1985-10-24 Tumor therapy Expired - Lifetime CA1281288C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66820084A 1984-11-05 1984-11-05
US06/668,200 1984-11-05
US72356585A 1985-04-15 1985-04-15
US06/723,565 1985-04-15

Publications (1)

Publication Number Publication Date
CA1281288C true CA1281288C (en) 1991-03-12

Family

ID=27099851

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000493821A Expired - Lifetime CA1281288C (en) 1984-11-05 1985-10-24 Tumor therapy

Country Status (5)

Country Link
JP (1) JPH0723309B2 (de)
CA (1) CA1281288C (de)
CH (1) CH667591A5 (de)
DE (1) DE3538619C2 (de)
GB (1) GB2171302B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0294380A4 (de) * 1986-02-18 1990-02-20 Biota Scient Management Stimulierung von angiogenese.
DE3728852C2 (de) * 1987-08-28 2003-06-18 Wilhelm Hoerrmann Arzneimittel zur Tumortherapie
EP0307390A3 (de) * 1987-09-04 1991-04-10 Merckle Gmbh Chemische Verbindung bestehend aus cis-3-hydroxyprolin zur therapeutischen Behandlung und Verfahren zu deren Herstellung
US5827874A (en) * 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
ES2152664T3 (es) * 1996-03-11 2001-02-01 Hoerrmann Wilhelm Combinacion de cis-4-hidroxi-l-prolina y n-metil-cis-4-hidroxi-l-prolina para aplicacion como agente terapeutico, especialmente para el tratamiento contra el cancer.
AU2698997A (en) * 1996-04-16 1997-11-07 Chephasaar Chem.-Pharm. Fabrik Gmbh Agent for inhibiting leukocyte invasion of tissues
DE10359829A1 (de) * 2003-12-12 2005-07-21 Salama, Zoser B., Dr.Rer.Nat. Verwendung von CHP als Inhibitor von Glutathion-S-Transferasen und Kollagen IV
DE10359828A1 (de) * 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
US20080176923A1 (en) * 2003-12-18 2008-07-24 Salama Zoser B Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors
WO2005120495A1 (en) * 2004-06-14 2005-12-22 Salama Zoser B Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
EP1957066A4 (de) 2005-11-11 2013-08-28 V Ravi Chandran Acetylierte aminosäuren als thrombozytenaggregationshemmer, nahrungs- und vitamin-ergänzungsmittel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7639M (de) * 1967-09-14 1970-02-02
US3932638A (en) * 1967-09-14 1976-01-13 Franco-Chimie S.A.R.L. Compositions and methods for wound healing
GB1399887A (en) * 1971-06-10 1975-07-02 Prockop D J Composition and methods for controlling collagen synthesis
FR2207702B1 (de) * 1972-11-23 1975-11-28 Rhone Poulenc Ind
JPS59164718A (ja) * 1983-03-10 1984-09-17 Advance Res & Dev Co Ltd 発癌予防剤

Also Published As

Publication number Publication date
DE3538619C2 (de) 1995-11-09
JPS61155324A (ja) 1986-07-15
CH667591A5 (de) 1988-10-31
GB2171302A (en) 1986-08-28
DE3538619A1 (de) 1986-05-07
GB8527159D0 (en) 1985-12-11
GB2171302B (en) 1989-08-23
JPH0723309B2 (ja) 1995-03-15

Similar Documents

Publication Publication Date Title
Huddlestone et al. Induction and kinetics of natural killer cells in humans following interferon therapy
Barranco et al. Treatment of relapsing polychondritis with dapsone
DE69532996T2 (de) Peptidanaloge des menschlichen basischen myelinproteins
Parfrey et al. Captopril-induced pemphigus
CA1281288C (en) Tumor therapy
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
US5200395A (en) Pharmaceutical composition of BUF-5 for treating anemia
Palmour et al. Characterization of a peptide from the serum of psychotic patients
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
CA2010321A1 (en) Lymphocyte-associated cell surface protein
Kawakita et al. Characterization of human megakaryocyte colony-stimulating factor in the urinary extracts from patients with aplastic anemia and idiopathic thrombocytopenic purpura
Guilhou et al. Somatostatin treatment of psoriasis
Konturek Comparison of pancreatic responses to natural and synthetic secretins in conscious cats
JP4463885B2 (ja) 劇症肝炎疾患治療剤
Jones et al. Neutrophil accumulation in vivo following the administration of chemotactic factors
Grójec et al. Effect of staphylococcal leukocidin on mouse leukocyte system
Rohatiner et al. Central nervous system toxicity of interferon
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
Türker et al. High degree of conversion of angiotensin I to angiotensin II in the mesenteric circulation of the isolated perfused terminal ileum of the cat
Chen et al. Recurrent agranulocytosis induced by two different antithyroid agents
Lee et al. The incorporation of 2-[14C] glycine into porcine lens protein
US3885030A (en) Medicine comprising lysine by-products
Woods Susceptibility to experimental pyelonephritis when hormonal hypertension is prevented by hypotensive drugs
Akmal et al. Intact and carboxyterminal PTH do not cross the blood-cerebrospinal fluid barrier
Masucci et al. Clinical evaluation of “quantitative” rheoencephalography

Legal Events

Date Code Title Description
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121205